Trump New Executive Orders Could Impact Indian Pharma Exports
News: President Donald Trump’s recent executive orders prioritize domestic pharmaceutical manufacturing in the U.S., posing major challenges for Indian drug exporters, especially in the generics market, according to a Nuvama Research report.
The move aims to re-shore production of APIs, KSMs, and raw materials, potentially disrupting global drug supply chains and reducing India’s cost advantage.
The orders also propose faster U.S. regulatory clearances, stricter compliance for foreign facilities, and higher fees for overseas manufacturers.
A possible requirement to disclose API origins could expose India’s reliance on Chinese imports, adding to scrutiny.
These measures reflect a broader focus on U.S. biosecurity and may significantly restructure the U.S. generics supply chain if fully implemented.
Source: The Economic Times
Join The Community
Recent News
-
Trump’s Tariffs Complicate Costly Questions Over China Supply -
BCAS Eases Cargo Re-Screening Rules, Boosting Speed of Air Freight Operations -
India-UK Trade Pact Sealed: 99% of Indian Exports to Enter UK Duty-Free -
Trump Warns India May Face 25% Tariffs -
Green Warehousing on the Rise in India as Global Firms Push for Sustainability
2 Comments